Genable is developing new gene medicines to treat "dominant" genetic diseases. Genable utilizes AAV vectors to obtain expression of RNA interference molecules which suppress the expression of faulty gene copies and replaces this with a gene which is refractory to suppression. Genable's first gene medicine - GT038 - is for treatment of patients with rhodopsin (RHO)-linked autosomal dominant retinitis pigmentosa.